TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. [electronic resource]
Producer: 20190501Description: 17 p. digitalISSN:- 1757-2215
- Antibiotics, Antineoplastic -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor -- metabolism
- Carcinoma, Ovarian Epithelial -- drug therapy
- DNA Topoisomerases, Type II -- genetics
- Doxorubicin -- analogs & derivatives
- Drug Resistance, Neoplasm
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Neoplasm Recurrence, Local
- Ovarian Neoplasms -- drug therapy
- Platinum -- pharmacology
- Polyethylene Glycols -- therapeutic use
- Retrospective Studies
No physical items for this record
Publication Type: Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.